Announcements and Notices - [Issue of Shares under a Specific Mandate]

Jiangsu Recbio Technology Co., Ltd. develops biotechnology products. The Company produces novel pharmaceuticals, pharmaceutical targets, and other products. Jiangsu Recbio Technology also operates import and export businesses.

(1) Proposed Issuance Of Domestic Shares
 (2) Signing Of Share Subscription Contract
With Conditions Precedent
And
 (3) Proposed Authorization To The Board
And Its Delegated Persons To Deal With Matters
Relating To The Issuance Of Domestic Shares

Announcements and Notices - [Other - Business Update]

Voluntary Announcement
Initiation Of Phase Iii Clinical Trial
In China Of The Company'S Novel
Adjuvanted Recombinant Shingles Vaccine Rec610

Financial Statements/ESG Information - [Interim/Half-Year Report]

2024 Interim Report

Announcements and Notices - [Interim Results]

Unaudited Interim Results Announcement For The Six Months Ended June 30, 2024

Announcements and Notices - [Date of Board Meeting]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jiangsu Recbio Technology (2179 HK)

(1) Proposed Issuance Of Domestic Shares (2) Signing Of Share Subscription Contract With Conditions Precedent And (3) Proposed Authorization To The Board And Its Delegated Persons To Deal With Matters Relating To The Issuance Of Domestic Shares

Voluntary Announcement Initiation Of Phase Iii Clinical Trial In China Of The Company'S Novel Adjuvanted Recombinant Shingles Vaccine Rec610

2024 Interim Report

Unaudited Interim Results Announcement For The Six Months Ended June 30, 2024

Date Of Board Meeting

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)